The latest price target for AVITA Medical (NASDAQ:RCEL) was reported by Cantor Fitzgerald on August 9, 2024. The analyst firm set a price target for $21.00 expecting RCEL to rise to within 12 months (a possible 137.56% upside). 11 analyst firms have reported ratings in the last year.

The latest analyst rating for AVITA Medical (NASDAQ:RCEL) was provided by Cantor Fitzgerald, and AVITA Medical reiterated their overweight rating.

There is no last upgrade for AVITA Medical

The last downgrade for AVITA Medical Inc happened on May 14, 2024 when Piper Sandler changed their price target from $21 to $9 for AVITA Medical Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of AVITA Medical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for AVITA Medical was filed on August 9, 2024 so you should expect the next rating to be made available sometime around August 9, 2025.

While ratings are subjective and will change, the latest AVITA Medical (RCEL) rating was a reiterated with a price target of $21.00 to $21.00. The current price AVITA Medical (RCEL) is trading at is $8.84, which is out of the analyst’s predicted range.